- Home
- BELFB vs PCRX Comparison
BELFB vs PCRX Comparison
Compare BELFB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- PCRX
- Stock Information
- Founded
- BELFB 1949
- PCRX 2006
- Country
- BELFB United States
- PCRX United States
- Employees
- BELFB N/A
- PCRX N/A
- Industry
- BELFB
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- PCRX Health Care
- Exchange
- BELFB Nasdaq
- PCRX Nasdaq
- Market Cap
- BELFB 1.1B
- PCRX 1.2B
- IPO Year
- BELFB N/A
- PCRX 2011
- Fundamental
- Price
- BELFB $86.07
- PCRX $25.16
- Analyst Decision
- BELFB Strong Buy
- PCRX Buy
- Analyst Count
- BELFB 3
- PCRX 9
- Target Price
- BELFB $100.00
- PCRX $26.22
- AVG Volume (30 Days)
- BELFB 102.4K
- PCRX 805.4K
- Earning Date
- BELFB 02-18-2025
- PCRX 02-27-2025
- Dividend Yield
- BELFB 0.33%
- PCRX N/A
- EPS Growth
- BELFB N/A
- PCRX N/A
- EPS
- BELFB 3.25
- PCRX N/A
- Revenue
- BELFB $534,792,000.00
- PCRX $694,957,000.00
- Revenue This Year
- BELFB N/A
- PCRX $5.55
- Revenue Next Year
- BELFB $0.77
- PCRX $5.64
- P/E Ratio
- BELFB $26.29
- PCRX N/A
- Revenue Growth
- BELFB N/A
- PCRX 4.40
- 52 Week Low
- BELFB $49.45
- PCRX $11.16
- 52 Week High
- BELFB $92.61
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- BELFB 63.38
- PCRX 52.48
- Support Level
- BELFB $80.29
- PCRX $25.41
- Resistance Level
- BELFB $88.65
- PCRX $26.89
- Average True Range (ATR)
- BELFB 2.89
- PCRX 1.18
- MACD
- BELFB 0.45
- PCRX -0.36
- Stochastic Oscillator
- BELFB 70.00
- PCRX 4.35
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.